Financials TaiMed Biologics Inc.

Equities

4147

TW0004147004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 2025-07-07			5-day change	1st Jan Change
87.50 ^TWD	-2.67%		-3.85%	+1.74%

06-22	TaiMed Biologics Inc. Initiates Phase 2b Clinical Study Preparation of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	CI
06-04	TaiMed Biologics Inc. Announces Election of New Chairperson Effective June 4, 2025	CI

Projected Income Statement: TaiMed Biologics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	722.5	413.4	563	491.8	610.2	680.2	700
Change	-	-42.78%	36.18%	-12.65%	24.07%	11.49%	2.9%
EBITDA ¹	7.022	-329.7	-35.41	-10.84	-97.98	-54	-
Change	-	-4,795.34%	89.26%	69.38%	-803.59%	44.89%	-
EBIT ¹	-132.8	-486.4	-191.9	-166.2	-252.3	-220.3	-68
Change	-	-266.35%	60.55%	13.36%	-51.76%	12.66%	69.14%
Interest Paid ¹	-	-	-	-14.81	-12.6	-13	-
Earnings before Tax (EBT) ¹	-183.3	-470.9	-269.3	-194.8	-201.8	-216.7	-54
Change	-	-156.91%	42.82%	27.66%	-3.6%	-7.35%	75.08%
Net income ¹	-183.3	-470.9	-269.3	-194.8	-201.8	-216.7	-54
Change	-	-156.91%	42.82%	27.66%	-3.6%	-7.35%	75.08%
Announcement Date	3/26/21	3/31/22	3/10/23	3/20/24	3/14/25	-	-

¹TWD in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2
Net sales ¹	179.1	151.9	152.3	91.26	155.2	91.12	75.86	40.67	99.28	96.58	326.5	71.77	104.2	157.6	158.2	178.9	146.9	138.5	145.8	176.2	164.2	169.8	181.5	175	161
Change	-	-15.15%	0.26%	-40.08%	70.06%	-41.28%	-16.75%	-46.39%	144.12%	-2.73%	238.04%	-78.02%	45.25%	51.14%	0.42%	13.1%	-17.89%	-5.74%	5.24%	20.91%	-6.8%	3.35%	6.92%	-3.58%	-8%
EBITDA ¹	32.71	-20.86	-77.56	-	-50.6	-29.32	-203.2	-63.11	-16.43	-	-	-32.02	-26.47	35.41	12.23	1.706	-2.593	-6.847	-90.25	4.972	4	-21	-40	-	-
Change	-	-163.79%	-271.78%	-	-	42.06%	-593.21%	68.94%	73.96%	-	-	-	17.33%	233.78%	-65.46%	-86.05%	-251.99%	-164.06%	-1,218.11%	105.51%	-19.55%	-625%	-90.48%	-	-
EBIT ¹	-2.098	-57.49	-116.7	-85.85	-89.82	-68.44	-242.2	-102.2	-55.56	-59.41	25.33	-71.14	-65.3	-3.289	-26.5	-37.05	-41.25	-45.42	-128.5	-33.33	-38	-68	-73.33	-17	-29
Change	-	-2,640.28%	-103.06%	26.46%	-4.62%	23.8%	-253.93%	57.81%	45.64%	-6.93%	142.63%	-380.88%	8.22%	94.96%	-705.69%	-39.82%	-11.34%	-10.1%	-183.03%	74.07%	-14.01%	-78.95%	-7.84%	76.82%	-70.59%
Charge d'intérêts ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.774	-3.756	-3.704	-2.9	-2.856	-3.144	-2.736	-4	-3	-3	-	-
Earnings before Tax (EBT) ¹	30.43	-46.54	-91.8	-	-99.26	-77.88	-298.7	-119.8	-75.77	-	-	-80.8	-47.84	-5.878	-60.29	-16.04	-27.53	-37.79	-120.5	-25.8	-37.33	-67	-72	-13	-25
Change	-	-252.97%	-97.24%	-	-	21.54%	-283.57%	59.91%	36.74%	-	-	-	40.79%	87.71%	-925.62%	73.4%	-71.66%	-37.25%	-218.81%	78.58%	-44.69%	-79.46%	-7.46%	81.94%	-92.31%
Net income ¹	30.43	-46.54	-91.8	4.915	-99.26	-77.88	-298.7	-119.8	-75.77	-35.98	-37.78	-80.8	-47.84	-5.878	-60.29	-16.04	-27.53	-37.79	-120.5	-25.8	-37.33	-67	-72	-13	-25
Change	-	-252.97%	-97.24%	105.35%	-2,119.53%	21.54%	-283.57%	59.91%	36.74%	52.52%	-5.02%	-113.87%	40.79%	87.71%	-925.62%	73.4%	-71.66%	-37.25%	-218.81%	78.58%	-44.69%	-79.46%	-7.46%	81.94%	-92.31%
Announcement Date	8/12/20	11/11/20	3/26/21	5/14/21	8/13/21	11/13/21	3/31/22	5/13/22	8/15/22	11/11/22	3/10/23	5/12/23	8/11/23	11/14/23	3/20/24	5/14/24	8/14/24	11/13/24	3/14/25	5/12/25	-	-	-	-	-

¹TWD in Million

Estimates

Forecast Balance Sheet: TaiMed Biologics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-36.1	-15.6	462	471	-85	227	-
Change	-	56.79%	3,061.54%	1.95%	-118.05%	367.18%	-
Announcement Date	3/26/21	3/31/22	3/10/23	3/20/24	3/14/25	-	-

¹TWD in Million

Estimates

Cash Flow Forecast: TaiMed Biologics Inc.

Fiscal Period: December	2020	2021	2023	2024	2025	2026
CAPEX ¹	53.61	8.173	5.937	8.056	7.5	6
Change	-	-84.76%	-	35.69%	-6.9%	-20%
Free Cash Flow (FCF) ¹	-254.3	-219.4	-31.54	-387.6	-144	-
Change	-	13.71%	-	-1,129.02%	62.85%	100%
Announcement Date	3/26/21	3/31/22	3/20/24	3/14/25	-	-

¹TWD in Million

Estimates

Forecast Financial Ratios: TaiMed Biologics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	0.97%	-79.75%	-6.29%	-2.21%	-16.06%	-7.94%	-
EBIT Margin (%)	-18.38%	-117.64%	-34.08%	-33.8%	-41.34%	-32.39%	-9.71%
EBT Margin (%)	-25.37%	-113.91%	-47.83%	-39.61%	-33.08%	-31.85%	-7.71%
Net margin (%)	-25.37%	-113.91%	-47.83%	-39.61%	-33.08%	-31.85%	-7.71%
FCF margin (%)	-35.2%	-53.08%	-	-6.41%	-63.53%	-21.17%	-
FCF / Net Income (%)	138.73%	46.6%	-	16.19%	192.04%	66.46%	-
Profitability
ROA	-3.69%	-9.6%	-	-4.87%	-4.54%	-4.04%	-1.55%
ROE	-5.24%	-14.82%	-9.52%	-7.38%	-6.13%	-5.04%	-2.35%
Financial Health
Leverage (Debt/EBITDA)	-	-	-13.04x	-43.43x	-	-4.2x	-
Debt / Free cash flow	-	-	-	-14.93x	-	-1.58x	-
Capital Intensity
CAPEX / Current Assets (%)	7.42%	1.98%	-	1.21%	1.32%	1.1%	0.86%
CAPEX / EBITDA (%)	763.51%	-2.48%	-	-54.75%	-8.22%	-13.89%	-
CAPEX / FCF (%)	-21.08%	-3.72%	-	-18.82%	-2.08%	-5.21%	-
Items per share
Cash flow per share ¹	-0.8007	-0.8375	-2.398	-0.1013	-1.415	-0.79	-
Change	-	-4.6%	-186.33%	95.78%	-1,296.94%	44.17%	-
Dividend per Share ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Book Value Per Share ¹	15.17	11.66	10.75	10.14	14.73	14.27	-
Change	-	-23.15%	-7.79%	-5.65%	45.25%	-3.16%	-
EPS ¹	-0.73	-1.87	-1.07	-0.77	-0.75	-0.7933	-0.2
Change	-	-156.16%	42.78%	28.04%	2.6%	-5.78%	74.79%
Nbr of stocks (in thousands)	252,220	252,311	252,374	252,999	273,080	273,119	273,119
Announcement Date	3/26/21	3/31/22	3/10/23	3/20/24	3/14/25	-	-